

Opportunity Title: FDA High Throughput Assessment of Opioid Drugs by

Automated Analysis Methods Fellowship

Opportunity Reference Code: FDA-CDER-2023-1348

Organization U.S. Food and Drug Administration (FDA)

Reference Code FDA-CDER-2023-1348

How to Apply Connect with ORISE...on the GO! Download the new ORISE GO mobile app in the Apple App.

<u>Store</u> or <u>Google Play Store</u> to help you stay engaged, connected, and informed during your ORISE experience and beyond!

A complete application consists of:

- An application
- Transcripts Click here for detailed information about acceptable transcripts
- A current resume/CV, including academic history, employment history, relevant experiences, and publication list
- One educational or professional recommendation

All documents must be in English or include an official English translation.

If you have questions, send an email to <a href="mailto:ORISE.FDA.CDER@orau.org">ORISE.FDA.CDER@orau.org</a>. Please include the reference code for this opportunity in your email.

Application Deadline 3/29/2024 11:59:00 PM Eastern Time Zone

**Description** \*Applications will be reviewed on a rolling-basis.

A research opportunity is available in the Office of Testing and Research (OTR), Office of Pharmaceutical Quality (OPQ) at the Center for Drug Evaluation and Research (CDER), Food and Drug Administration (FDA), located in Saint Louis, Missouri. CDER regulates over-the-counter and prescription drugs, including biological therapeutics and generic drugs. This research covers more than just medicines.

The project will involve the development and validation of methods for high-throughput characterization and quantification of opioid drug products. The project consists developing sample preparation procedures utilizing an automatic sample preparation system, characterization of the performance of the preparation methods, and validation. The prepared samples will be tested for potency of active ingredients and impurities characterization using high-throughput HPLC and mass spectrometry-based techniques.

Under the guidance of the mentor the participant will gain valuable on-site training and diversified experience that will help the participant to prepare for a career in government or pharmaceutical related jobs. The participant will be given the opportunity to enhance their communication skills through preparation of manuscripts, oral presentations and posters. The participant will also learn new techniques and focus on particular areas of pharmaceutical analysis that are often beyond the scope of formal undergraduate or graduate programs.

This program, administered by ORAU through its contract with the U.S. Department of Energy to manage the Oak Ridge Institute for Science and Education, was established through an interagency agreement between DOE and FDA. **The initial appointment is for one year,** but may be



OAK RIDGE INSTITUTE

Generated: 8/19/2024 7:53:05 PM



Opportunity Title: FDA High Throughput Assessment of Opioid Drugs by

Automated Analysis Methods Fellowship

Opportunity Reference Code: FDA-CDER-2023-1348

renewed upon recommendation of FDA contingent on the availability of funds. The participant will receive a monthly stipend commensurate with educational level and experience. Proof of health insurance is required for participation in this program. The appointment is full-time at FDA in the St. Louis, Missouri, area. Participants do not become employees of FDA, DOE or the program administrator, and there are no employment-related benefits.

Completion of a successful background investigation by the Office of Personnel Management is required for an applicant to be on-boarded at FDA. OPM can complete a background investigation only for individuals, including non-US Citizens, who have resided in the US for a total of three of the past five years.

# **FDA Ethics Requirements**

If an ORISE Fellow, to include their spouse and minor children, reports what is identified as a Significantly Regulated Organization (SRO) or prohibited investment fund financial interest in any amount, or a relationship with an SRO, except for spousal employment with an SRO, and the individual will not voluntarily divest the financial interest or terminate the relationship, then the individual is not placed at FDA. For additional requirements, see FDA Ethics for Nonemployee Scientists.

FDA requires ORISE participants to read and sign their FDA Education and Training Agreement within 30 days of his/her start date, setting forth the conditions and expectations for his/her educational appointment at the agency. This agreement covers such topics as the following:

- · Non-employee nature of the ORISE appointment;
- · Prohibition on ORISE Fellows performing inherently governmental functions:
- · Obligation of ORISE Fellows to convey all necessary rights to the FDA regarding intellectual property conceived or first reduced to practice during their fellowship;
- The fact that research materials and laboratory notebooks are the property of the FDA;
- · ORISE fellow's obligation to protect and not to further disclose or use non-public information.

Qualifications The qualified candidate should have received a doctoral degree in one of the related fields. Degree must have been received within the past five years.

## Preferred Skills:

- Hands-on experience in liquid chromatographic and mass spectrometric techniques and application of those techniques to trace quantitative analysis.
- Training or experience in analytical method development for complex matrices is also highly desirable.

• **Degree:** Doctoral Degree received within the last 60 month(s). Eligibility

Generated: 8/19/2024 7:53:05 PM



Opportunity Title: FDA High Throughput Assessment of Opioid Drugs by

Automated Analysis Methods Fellowship

Opportunity Reference Code: FDA-CDER-2023-1348

- Requirements Discipline(s):
  - Chemistry and Materials Sciences (1\_●)
  - Life Health and Medical Sciences (1●)

Affirmation I have lived in the United States for at least 36 out of the past 60 months. (36 months do not have to be consecutive.) I have read the FDA Ethics Requirements.

and

I have read the FDA Ethics Requirements.

Generated: 8/19/2024 7:53:05 PM